Posted by on October 21, 2020 9:16 am
Categories: CRISPR-Google

CRISPR Therapeutics’ CAR-T treatment shows encouraging results – STAT

An off-the-shelf CAR-T cell therapy developed by CRISPR Therapeutics induced complete remissions in some patients with advanced B-cell lymphoma, but a patient death was also deemed to be related to the treatment, the company said Wednesday.

The clinical trial results are preliminary and represent an effort by CRISPR Therapeutics to expand CRISPR-edited treatments into cancer care. The company, in partnership with Vertex Pharmaceuticals, is also conducting clinical trials of CRISPR-based therapies for patients with rare, inherited blood disorders.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Published at Wed, 21 Oct 2020 11:06:35 +0000